US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

179.25 -2.82 (-1.55%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
From Grabar Law Office
Via GlobeNewswire
News headline image
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) ↗
 
Via Benzinga
News headline image
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
From Grabar Law Office
Via GlobeNewswire
News headline image
SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); and Maison Solutions
From Grabar Law Office
Via GlobeNewswire
News headline image
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stocks Edge Higher Despite Trade, Economic Jitters ↗
Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Why Shares of Axsome Therapeutics Slumped Today ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week ↗
The company posted mixed results for its depression treatment, noting it appears to work in a smaller patient group. 
Via Investor's Business Daily
News headline image
Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder ↗
Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients supports plans for a new study in 2025. 
Via Benzinga
News headline image
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗
Via The Motley Fool
News headline image
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. ↗
The company is working on a non-stimulant approach to treating ADHD. 
Via Investor's Business Daily
News headline image
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal ↗
Axsome's solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile. 
Via Benzinga
News headline image
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs ↗
Axsome's Symbravo outperformed oral CGRP inhibitors in a Phase 3 trial, improving migraine pain relief, symptom control, and return to daily activities. 
Via Benzinga
News headline image
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride ↗
CEO Herriot Tabuteau struck an optimistic tone, citing strong commercial growth, a rapidly advancing pipeline, and the recent U.S. approval of Symbravo for migraine treatment. 
Via Stocktwits
News headline image
US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday? ↗
Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday. 
Via Benzinga
News headline image
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025. 
Via Benzinga
News headline image
Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript ↗
AXSM earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Axsome Therapeutics Revenue Surges 66% ↗
Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated losses. 
Via The Motley Fool
News headline image
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 18, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >